Sagent Pharmaceuticals,
Inc. SGNT today announced that due to the current critical shortage
of Sodium Bicarbonate Injection, USP in the United States market, Sagent, in
cooperation with the U.S. Food and Drug Administration ("FDA"), has initiated
the temporary importation into the U.S. of a non-FDA approved 8.4% Sodium
Bicarbonate Injection (1 mEQ/mL) from Phebra Pty Ltd., an Australian
manufacturer. Please refer to the Dear Healthcare Provider Letter, posted on
the FDA website, for further information about availability of supply.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in